Subcutaneous Tissue
- XW013 - Percutaneous
- XW0131
- XW01318 - Introduction Subcutaneous Tissue to New Technology Group 8 with Daratumumab and Hyaluronidase-fihj, Percutaneous Approach
- XW0132
- XW01329 - Introduction Subcutaneous Tissue to New Technology Group 9 with Talquetamab Antineoplastic, Percutaneous Approach
- XW0134
- XW01348 - Introduction Subcutaneous Tissue to New Technology Group 8 with Teclistamab Antineoplastic, Percutaneous Approach
- XW0136
- XW0136A - Introduction Subcutaneous Tissue to New Technology Group 10 with Dasiglucagon, Percutaneous Approach
- XW0139
- XW01397 - Introduction Subcutaneous Tissue to New Technology Group 7 with Satralizumab-mwge, Percutaneous Approach
- XW013F
- XW013F5 - Introduction Subcutaneous Tissue to New Technology Group 5 with Other New Technology Therapeutic Substance, Percutaneous Approach
- XW013G
- XW013G6 - Introduction Subcutaneous Tissue to New Technology Group 6 with REGN-COV2 Monoclonal Antibody, Percutaneous Approach
- XW013H
- XW013H6 - Introduction Subcutaneous Tissue to New Technology Group 6 with Other New Technology Monoclonal Antibody, Percutaneous Approach
- XW013K
- XW013K6 - Introduction Subcutaneous Tissue to New Technology Group 6 with Leronlimab Monoclonal Antibody, Percutaneous Approach
- XW013L
- XW013L9 - Introduction Subcutaneous Tissue to New Technology Group 9 with Elranatamab Antineoplastic, Percutaneous Approach
- XW013S
- XW013S6 - Introduction Subcutaneous Tissue to New Technology Group 6 with COVID-19 Vaccine Dose 1, Percutaneous Approach
- XW013S9 - Introduction Subcutaneous Tissue to New Technology Group 9 with Epcoritamab Monoclonal Antibody, Percutaneous Approach
- XW013T
- XW013T6 - Introduction Subcutaneous Tissue to New Technology Group 6 with COVID-19 Vaccine Dose 2, Percutaneous Approach
- XW013U
- XW013U6 - Introduction Subcutaneous Tissue to New Technology Group 6 with COVID-19 Vaccine, Percutaneous Approach
- XW013V
- XW013V7 - Introduction Subcutaneous Tissue to New Technology Group 7 with COVID-19 Vaccine Dose 3, Percutaneous Approach
- XW013W
- XW013W5 - Introduction Subcutaneous Tissue to New Technology Group 5 with Caplacizumab, Percutaneous Approach
- XW013W7 - Introduction Subcutaneous Tissue to New Technology Group 7 with COVID-19 Vaccine Booster, Percutaneous Approach
- XW01X - External
- XW01X2
- XW01X27 - Introduction Subcutaneous Tissue to New Technology Group 7 with Anacaulase-bcdb, External Approach